# NCT01824875 (NCT01824875)

> Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01824875
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
- Interventions: temozolomide; capecitabine
- Enrollment: 144
- Primary outcome: Progression-free Survival

## Commentary we found

- YouTube: 4
- X threads: 4
- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01824875

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01824875", "email": "<work email>"}; the inbox owner confirms by the emailed link.